Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease

Journal of Hepatology

Volumn 66, Issue 3, 2017, Pages 610-618

  Lackner, Carolin ^a   Spindelboeck, Walter ^a   Haybaeck, Johannes ^a   Douschan, Philipp ^a   Rainer, Florian ^a   Terracciano, Luigi ^b   Haas, Josef ^a   Berghold, Andrea ^a   Bataller, Ramon ^c   Stauber, Rudolf E ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Alcoholic; Biopsy; Hepatic fibrosis; Liver diseases; Liver failure; Retrospective studies

Indexed keywords

ALCOHOL; BILIRUBIN; BIOCHEMICAL MARKER;

ADULT; AGED; ALCOHOL ABSTINENCE; ALCOHOL ABUSE; ALCOHOL LIVER DISEASE; ALCOHOLISM; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL FEATURE; CONTROLLED STUDY; DECOMPENSATED LIVER CIRRHOSIS; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER BIOPSY; LIVER FAILURE; LIVER FIBROSIS; LIVER HISTOLOGY; LONG TERM CARE; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR; BLOOD; COHORT ANALYSIS; KAPLAN MEIER METHOD; METABOLISM; PATHOLOGY; PSYCHOLOGY; YOUNG ADULT;

ADULT; AGED; ALCOHOL ABSTINENCE; BILIRUBIN; COHORT STUDIES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER DISEASES, ALCOHOLIC; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 85009270159     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.11.011     Document Type: Article

References (55)

1. [1] Rehm, J., Zatonksi, W., Taylor, B., Anderson, P., Epidemiology and alcohol policy in Europe. Addiction 106 (2011), 11–19.
2. [2] Poznyak, V., Fleischmann, A., Rekve, D., Rylett, M., Rehm, J., Gmel, G., The world health organization's global monitoring system on alcohol and health. Alcohol Res 35 (2013), 244–249.
3. [3] Porter, H.P., Simon, F.R., Pope, C.E. 2nd, Volwiler, W., Fenster, L.F., Corticosteroid therapy in severe alcoholic hepatitis. A double-blind drug trial. N Engl J Med 284 (1971), 1350–1355.
4. [4] Thursz, M.R., Richardson, P., Allison, M., Austin, A., Bowers, M., Day, C.P., et al. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med 372 (2015), 1619–1628.
5. [5] Gao, B., Bataller, R., Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology 141 (2011), 1572–1585.
6. [6] Bataller, R., Gao, B., Liver fibrosis in alcoholic liver disease. Semin Liver Dis 35 (2015), 146–156.
7. [7] Burt, A.D., Lackner, C., Tiniakos, D.G., Diagnosis and assessment of NAFLD: definitions and histopathological classification. Semin Liver Dis 35 (2015), 207–220.
8. [8] European Association for the Study of Liver. EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol 57 (2012), 399–420.
9. [9] O'Shea, R.S., Dasarathy, S., McCullough, A.J. Practice Guideline Committee of the American Association for the Study of Liver Diseases, Practice Parameters Committee of the American College of Gastroenterology. Alcoholic liver disease. Hepatology 51 (2010), 307–328.
10. [10] Maddrey, W.C., Boitnott, J.K., Bedine, M.S., Weber, F.L. Jr, Mezey, E., White, R.I. Jr., Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 75 (1978), 193–199.
11. [11] Carithers, R.L. Jr, Herlong, H.F., Diehl, A.M., Shaw, E.W., Combes, B., Fallon, H.J., et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Ann Intern Med 110 (1989), 685–690.
12. [12] Dunn, W., Jamil, L.H., Brown, L.S., Wiesner, R.H., Kim, W.R., Menon, K.V., et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology 41 (2005), 353–358.
13. [13] Srikureja, W., Kyulo, N.L., Runyon, B.A., Hu, K.Q., MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis. J Hepatol 42 (2005), 700–706.
14. [14] Forrest, E.H., Evans, C.D., Stewart, S., Phillips, M., Oo, Y.H., McAvoy, N.C., et al. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut 54 (2005), 1174–1179.
15. [15] Louvet, A., Naveau, S., Abdelnour, M., Ramond, M.J., Diaz, E., Fartoux, L., et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology 45 (2007), 1348–1354.
16. [16] Dominguez, M., Rincon, D., Abraldes, J.G., Miquel, R., Colmenero, J., Bellot, P., et al. A new scoring system for prognostic stratification of patients with alcoholic hepatitis. Am J Gastroenterol 103 (2008), 2747–2756.
17. [17] Altamirano, J., Miquel, R., Katoonizadeh, A., Abraldes, J.G., Duarte-Rojo, A., Louvet, A., et al. A histologic scoring system for prognosis of patients with alcoholic hepatitis. Gastroenterology 146 (2014), 1231–1239, e1–e6.
18. [18] Reid, M.C., Fiellin, D.A., O'Connor, P.G., Hazardous and harmful alcohol consumption in primary care. Arch Intern Med 159 (1999), 1681–1689.
19. [19] Rockey, D.C., Caldwell, S.H., Goodman, Z.D., Nelson, R.C., Smith, A.D., American Association for the Study of Liver Diseases. Liver biopsy. Hepatology 49 (2009), 1017–1044.
20. [20] Mathurin, P., Lucey, M.R., Management of alcoholic hepatitis. J Hepatol 56 (2012), S39–S45.
21. [21] Pugh, R.N., Murray-Lyon, I.M., Dawson, J.L., Pietroni, M.C., Williams, R., Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60 (1973), 646–649.
22. [22] Yip, W.W., Burt, A.D., Alcoholic liver disease. Semin Diagn Pathol 23 (2006), 149–160.
23. [23] Chedid, A., Mendenhall, C.L., Gartside, P., French, S.W., Chen, T., Rabin, L., Prognostic factors in alcoholic liver disease. VA Cooperative Study Group. Am J Gastroenterol 86 (1991), 210–216.
24. [24] Bouchier, I.A., Hislop, W.S., Prescott, R.J., A prospective study of alcoholic liver disease and mortality. J Hepatol 16 (1992), 290–297.
25. [25] Pessione, F., Ramond, M.J., Peters, L., Pham, B.N., Batel, P., Rueff, B., et al. Five-year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis, smoking and abstinence. Liver Int 23 (2003), 45–53.
26. [26] Cortez-Pinto, H., Baptista, A., Camilo, M.E., De Moura, M.C., Nonalcoholic steatohepatitis–a long-term follow-up study: comparison with alcoholic hepatitis in ambulatory and hospitalized patients. Dig Dis Sci 48 (2003), 1909–1913.
27. [27] Naveau, S., Gaude, G., Asnacios, A., Agostini, H., Abella, A., Barri-Ova, N., et al. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology 49 (2009), 97–105.
28. [28] Sandahl, T.D., Jepsen, P., Thomsen, K.L., Vilstrup, H., Incidence and mortality of alcoholic hepatitis in Denmark 1999–2008: a nationwide population based cohort study. J Hepatol 54 (2011), 760–764.
29. [29] Younossi, Z.M., Stepanova, M., Rafiq, N., Makhlouf, H., Younoszai, Z., Agrawal, R., et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology 53 (2011), 1874–1882.
30. [30] Ekstedt, M., Hagstrom, H., Nasr, P., Fredrikson, M., Stal, P., Kechagias, S., et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61 (2015), 1547–1554.
31. [31] Williams, C.D., Stengel, J., Asike, M.I., Torres, D.M., Shaw, J., Contreras, M., et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 140 (2011), 124–131.
32. [32] Elphick, D.A., Dube, A.K., McFarlane, E., Jones, J., Gleeson, D., Spectrum of liver histology in presumed decompensated alcoholic liver disease. Am J Gastroenterol 102 (2007), 780–788.
33. [33] Masson, S., Emmerson, I., Henderson, E., Fletcher, E.H., Burt, A.D., Day, C.P., et al. Clinical but not histological factors predict long-term prognosis in patients with histologically advanced non-decompensated alcoholic liver disease. Liver Int 34 (2014), 235–242.
34. [34] Orrego, H., Blake, J.E., Blendis, L.M., Medline, A., Prognosis of alcoholic cirrhosis in the presence and absence of alcoholic hepatitis. Gastroenterology 92 (1987), 208–214.
35. [35] Nakano, M., Worner, T.M., Lieber, C.S., Perivenular fibrosis in alcoholic liver injury: ultrastructure and histologic progression. Gastroenterology 83 (1982), 777–785.
36. [36] Worner, T.M., Lieber, C.S., Perivenular fibrosis as precursor lesion of cirrhosis. JAMA 254 (1985), 627–630.
37. [37] Savolainen, V., Perola, M., Lalu, K., Penttila, A., Virtanen, I., Karhunen, P.J., Early perivenular fibrogenesis–precirrhotic lesions among moderate alcohol consumers and chronic alcoholics. J Hepatol 23 (1995), 524–531.
38. [38] Rangwala, F., Guy, C.D., Lu, J., Suzuki, A., Burchette, J.L., Abdelmalek, M.F., et al. Increased production of sonic hedgehog by ballooned hepatocytes. J Pathol 224 (2011), 401–410.
39. [39] Coates, R.A., Halliday, M.L., Rankin, J.G., Feinman, S.V., Fisher, M.M., Risk of fatty infiltration or cirrhosis of the liver in relation to ethanol consumption: a case-control study. Clin Invest Med 9 (1986), 26–32.
40. [40] Sato, N., Lindros, K.O., Baraona, E., Ikejima, K., Mezey, E., Järveläinen, H.A., et al. Sex difference in alcohol-related organ injury. Alcohol Clin Exp Res 25 (2001), 40S–45S.
41. [41] Batey, R.G., Burns, T., Benson, R.J., Byth, K., Alcohol consumption and the risk of cirrhosis. Med J Aust 156 (1992), 413–416.
42. [42] Pares, A., Caballeria, J., Bruguera, M., Torres, M., Rodes, J., Histological course of alcoholic hepatitis. Influence of abstinence, sex and extent of hepatic damage. J Hepatol 2 (1986), 33–42.
43. [43] Krasner, N., Davis, M., Portmann, B., Williams, R., Changing pattern of alcoholic liver disease in Great Britain: relation to sex and signs of autoimmunity. Br Med J 1 (1977), 1497–1500.
44. [44] Tuyns, A.J., Pequignot, G., Greater risk of ascitic cirrhosis in females in relation to alcohol consumption. Int J Epidemiol 13 (1984), 53–57.
45. [45] Yamada, S., Matsuoka, H., Harada, Y., Momosaka, Y., Izumi, H., Kohno, K., et al. Effect of long-term ethanol consumption on ability to produce cytokine-induced neutrophil chemoattractant-1 in the rat liver and its gender difference. Alcohol Clin Exp Res 23 (1999), 61S–66S.
46. [46] Thurman, R.G., Sex-related liver injury due to alcohol involves activation of Kupffer cells by endotoxin. Can J Gastroenterol 14 (2000), 129D–135D.
47. [47] Gallucci, R.M., Sloan, D.K., O'Dell, S.J., Reinke, L.A., Differential expression of liver interleukin-6 receptor-alpha in female vs. male ethanol-consuming rats. Alcohol Clin Exp Res 28 (2004), 365–373.
48. [48] Potts, J.R., Howard, M.R., Verma, S., Recurrent severe alcoholic hepatitis: clinical characteristics and outcomes. Eur J Gastroenterol Hepatol 25 (2013), 659–664.
49. [49] O'Shea, R.S., Dasarathy, S., McCullough, A.J., Alcoholic liver disease. Am J Gastroenterol 105 (2010), 14–32 [Quiz 33].
50. [50] Powell, W.J. Jr, Klatskin, G., Duration of survival in patients with Laennec's cirrhosis. Influence of alcohol withdrawal, and possible effects of recent changes in general management of the disease. Am J Med 44 (1968), 406–420.
51. [51] Borowsky, S.A., Strome, S., Lott, E., Continued heavy drinking and survival in alcoholic cirrhotics. Gastroenterology 80 (1981), 1405–1409.
52. [52] Miller, W.R., Walters, S.T., Bennett, M.E., How effective is alcoholism treatment in the United States?. J Stud Alcohol 62 (2001), 211–220.
53. [53] Grant, B.F., Barriers to alcoholism treatment: reasons for not seeking treatment in a general population sample. J Stud Alcohol 58 (1997), 365–371.
54. [54] Eckardt, M.J., Rawlings, R.R., Martin, P.R., Biological correlates and detection of alcohol abuse and alcoholism. Prog Neuropsychopharmacol Biol Psychiatry 10 (1986), 135–144.
55. [55] Addolorato, G., Leggio, L., Ferrulli, A., Cardone, S., Vonghia, L., Mirijello, A., et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 370 (2007), 1915–1922.